EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Starton Therapeutics's enterprise value is $0.00 Mil.
Starton Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-7.23 Mil. Therefore, Starton Therapeutics's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Starton Therapeutics's EV-to-EBITDA or its related term are showing as below:
STA's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.67 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Starton Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Starton Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Starton Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Starton Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starton Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starton Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Starton Therapeutics's EV-to-EBITDA falls into.
Starton Therapeutics's current Enterprise Value is $0.00 Mil.
Starton Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Starton Therapeutics's PE Ratio for today is calculated as:
Starton Therapeutics's share price for today is $0.00.
Starton Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Starton Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Starton Therapeutics (Starton Therapeutics) Business Description
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STA has been successfully added to your